Aclaris Therapeutics ACRS Deferred revenue, net of current portion

Deferred revenue, net of current portion at other companies

Kymera TherapeuticsKYMR

——

CytomX TherapeuticsCTMX

——

Arcus BiosciencesRCUS

——

Alumis Inc.ALMS

——

Janux TherapeuticsJANX

——

Kura OncologyKURA

——

Other financials

Income statement

See full

Revenue$2.0M+37.2%

Gross profit$1.6M+68.7%

Operating income-$22.2M-22.7%

Net income-$19.8M-31.4%

EPS (diluted)-$0.15-25.0%

Balance sheet

See full

Cash & equivalents$28.7M-5.6%

Total debt$2.0M-20.1%

Total equity$143.6M-0.3%

Total assets$198.7M+0.3%

Cash flow

See full

Operating cash flow-$18.1M-39.0%

CapEx$13.0K-69.8%

Free cash flow-$18.2M-38.6%

Valuation

See full

Market cap$685.75M+337%

Enterprise value$659.07M+410%

P/S82×+73.1×

Profitability

See full

Gross margin76.3%-9.7pp

Operating margin-961.9%+259pp

Net margin-832.6%+132pp

FCF margin-624.9%—

Returns & leverage

See full

Return on equity-48.4%-15.4pp

Debt / equity0×0.0×

Current ratio4×-1.0×

Where this comes from

Reported directly by Aclaris Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: Aclaris Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aclaris Therapeutics's deferred revenue, net of current portion.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Aclaris Therapeutics's deferred revenue, net of current portion?: Aclaris Therapeutics (ACRS) reported deferred revenue, net of current portion of $15.29M in Q1 2026.
How has Aclaris Therapeutics's deferred revenue, net of current portion changed year-over-year?: Aclaris Therapeutics's deferred revenue, net of current portion decreased by 20.4% year-over-year, from $19.21M to $15.29M.